Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board

Saturday, December 22, 2007 General News J E 4
EMERYVILLE, Calif., Dec. 21 NeurobiologicalTechnologies, Inc. (NTI (R)) (Nasdaq: NTII) today announced the retirement ofDr. Ronald E. Cape as Director, effective December 31, 2007.

Paul Freiman, president and chief executive officer stated, "We haveaccepted Dr. Cape's resignation upon the occasion of his 75th birthday. Dr.Cape is a legend in the biotechnology industry and his service on our boardhas been outstanding. Prior to joining the board, Dr. Cape served as anadvisor to the company and we are pleased that he has agreed to continue to beavailable to advise us."

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifyingand acquiring promising drug candidates and in designing and managinglate-stage clinical trials for central nervous system conditions. The Companyis currently developing Viprinex(TM) (ancrod), a novel reperfusion agent thatis in pivotal Phase 3 trials for the treatment of acute ischemic stroke.

SOURCE Neurobiological Technologies, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
FDA Warning for N-9 - an Opportunity for VivaGel(R...
Lexicon Files Investigational New Drug Application...